Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co. develops gene therapy product candidates designed to provide efficacy by inducing sustained expression of a therapeutic protein. Co.'s main capabilities include vector discovery, preclinical and clinical development, and in-house manufacturing knowledge, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Co.'s lead product candidate ADVM-022 is a single intravitreal injection gene therapy targeting the treatment of wet age-related macular degeneration and diabetic retinopathy. We show 28 historical shares outstanding datapoints in our ADVM shares outstanding history coverage, used to compute ADVM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADVM market cap history over the course of time is important for investors
interested in comparing ADVM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADVM versus a peer is one thing; comparing
ADVM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADVM can fluctuate over the course of history.
With this page we aim to empower investors researching ADVM by allowing them to research the ADVM market cap history. |
Video: The Importance of Market Cap
